Sorrento, Under Shadow Of Chapter 11, Looks To Move BTK Inhibitor Into Phase III
Executive Summary
The biotech announced promising Phase IIa results for abivertinib in marginal zone lymphoma and is in talks with Chinese regulators about a Phase III trial.